Posted by eoJC
on November 06, 2000 at 23:40:58:
In Reply to: Re: Promising Parkinson's treatments on the horizon posted by Darrell on October 17, 2000 at 02:05:53:
Novel Dopamine Reuptake Blocker Demonstrates Significant Effect in Early/Moderate PD Model
BOSTON--(BUSINESS WIRE)--Nov. 6, 2000-- Boston Life Sciences, Inc. (NASDAQ: BLSI - news) announced that the Company's lead therapeutic compound for the potential treatment of PD successfully reversed the movement abnormalities exhibited by PD in primates in a more extensive second round of experiments. ``This further success appears very exciting because the characteristics and method of action of this drug offers the potential that side effects will be greatly reduced compared with other PD therapeutics currently available,'' commented Dr. Marc Lanser, Chief Scientific Officer of BLSI.
The Company believes that the strategy of DAT blockade represents a new approach to the treatment of PD in humans. The Company has initiated a series of pre-clinical studies necessary for the filing of an IND, with the intention of starting human clinical trials sometime next year.
The new drug, O-1369 is a small molecule that binds with extremely high selectivity to the dopamine transporter (DAT) thereby blocking the reuptake of dopamine from nerve connections. This blockade results in an increase in local dopamine concentrations at the nerve junctions and thus compensates for the decreased dopamine production characteristic of PD. This restoration of dopamine levels in the midbrain restores normal motor function in experimental PD. A single injection of O-1369 normalized their range of movement. The duration of action of the single dose of drug was 8 - 12 hours. A positive dose response effect to the drug was correlated with a dose-related improvement in motion.
``Our PD therapeutic grows out of the expertise of our collaborating scientists in the area of neurochemistry and its effects upon mood and behavior. In addition to Altropane and Fluorotec (our imaging agents for the diagnosis of PD and Attention Deficit Hyperactivity Disorder), this development program has expanded to potentially include diagnostics and therapeutics for depression. The depth of this effort has turned out to be far greater than our original interest in PD imaging,'' added David Hillson, President and Chief Executive Officer.